GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nephros Inc (FRA:NPJP) » Definitions » ROE % Adjusted to Book Value

Nephros (FRA:NPJP) ROE % Adjusted to Book Value : 9.51% (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Nephros ROE % Adjusted to Book Value?

Nephros's ROE % for the quarter that ended in Dec. 2024 was 17.12%. Nephros's PB Ratio for the quarter that ended in Dec. 2024 was 1.80. Nephros's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was 9.51%.


Nephros ROE % Adjusted to Book Value Historical Data

The historical data trend for Nephros's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nephros ROE % Adjusted to Book Value Chart

Nephros Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -5.24 0.50

Nephros Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.16 -2.80 -5.24 4.15 9.51

Competitive Comparison of Nephros's ROE % Adjusted to Book Value

For the Medical Instruments & Supplies subindustry, Nephros's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nephros's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nephros's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Nephros's ROE % Adjusted to Book Value falls into.


;
;

Nephros ROE % Adjusted to Book Value Calculation

Nephros's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.90% / 1.80
=0.50%

Nephros's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=17.12% / 1.80
=9.51%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nephros ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Nephros's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Nephros Business Description

Traded in Other Exchanges
Address
380 Lackawanna Place, South Orange, NJ, USA, 07079
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.

Nephros Headlines

No Headlines